Biologiske lægemidler til behandling af ikke-cancerrelaterede sygdommeTumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease

Biological response modifiers are modified (poly) peptides from living organisms designed to modulate a specific biologic process. Biotechnology has led to the rapid development of recombinant drugs for treatment of many immunoinflammatory diseases. In this article, we briefly describe the main types of these therapeutic proteins, their mechanisms of action and side-effects
Udgivelsesdato: 2008/6/9